Abstract:The oceans cover about 96.5% of all the Earth's water and are virtually unexploited resources for novel drug discovery. Members of almost every phylum are found in the oceans, whereas twelve phyla are exclusively marine. A very limited fraction of marine compounds have been tested in clinically relevant bioassays. Higher resistance of pathogenic microorganisms to antibiotics and disease cells to antitumor medications requires a new phase of novel medicines. The study aims to explore the potential of marine sponges as natural inhibitors for breast cancer therapy using an optimized in-silico technique. We perform in -silico analysis for around two hundred and seventy-two (272) marine sponge compounds against ERα of breast cancer using molecular docking and dynamics techniques. The results of the current study were carefully used to screen the compounds with the potential to inhibit ERα of breast cancer. For instance, molecular docking analysis reveals that six top-hit selected ligands L1 (Di(IH-indol-3-yl) methanone), L2 (1,2-Bis (1H-indol-3-yl)ethane-1,2-dione), L3 2-(4-benzylpiperidin-1-yl)1-(1H-indol-3-yl)ethenone), L4 ( 5H-Pyrido[4,3-b]carbazole-5,11(6H)-dione), L5 (4H-pyrido[2,3,4-Kl]acridine-4-one), and L6 15-methyl-2, 12,15-triazapentacyclo [11.7.1.03,8,09,21.014,19]henicosa-1,3,5,7,9(21),10,12,14(19),16-nonaene-18,20-dione) show docking scores values ranging from -9.2 kcal/mole to -9.5 kcal/mol in comparison to reference drug inhibitor -8.6 kcal/mole to -9.5 kcal/mol. For comparison purposes, reference drug candidates like tamoxifen, ospemifene, and quinestrol have been studied under the same in -silico methodology. The ligand-protein interactions displayed various types of intermolecular interactions, including hydrogen bond formationand hydrophobic and π-π stacking interactions towards the active site of the protein. Explicit molecular dynamic (MD) simulations for 120 ns were executed to mimic the in-vitro aqueous environment and stability pattern of ligand-protein complexes through RMSD, RMSF, Rg, SASA, and intermolecular H-bond. Furthermore, MM/PBSA calculation also confirmed the good binding free energy ( ΔGbind ) of L1 (-22.63 kcal/mol), L2 (-13.81 kcal/mol), L3 (-19.23 kcal/mol), L4 (-24.50 kcal/mol), L5 (-14.44 kcal/mol), and L6 (-8.16 kcal/mol) towards ERα (1gwr). Additionally, the ADMET prediction of top-hit ligands was observed to have good drug-likeness criteria (Lipinski RO5) and pharmacokinetic properties. The in-silico approach identified ligands L1, L2, L3, L4, L5 , and L6 as a promising inhibitor of ERα of breast cancer, suggesting in vivo/in vitro studies to investigate their inhibitory potentials further.

Virtual screening of potential inhibitor against breast cancer-causing estrogen receptor alpha (ERα): molecular docking and dynamic simulations

In Silico Screening of Marine Compounds as an Emerging and Promising Approach against Estrogen Receptor Alpha-Positive Breast Cancer

Computational prediction for designing novel ketonic derivatives as potential inhibitors for breast cancer: A trade-off between drug likeness and inhibition potency

In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer

Estrogen Receptor Alpha Binders for Hormone-Dependent Forms of Breast Cancer: e-QSAR and Molecular Docking Supported by X-ray Resolved Structures

In-silico identification of potential inhibitors targeting the DNA binding domain of estrogen receptor α for the treatment of hormone therapy-resistant breast cancer

Identification of HER2 inhibitors from curcumin derivatives using combination of in silico screening and molecular dynamics simulation

Comprehensive Computational Screening and Analysis of Natural Compounds Reveals Promising Estrogen Receptor Alpha Inhibitors for Breast Cancer Therapy

Identifying Potent Breast Cancer Inhibitors Against ERα Target Using Pharmacophore Model, 3D‐QSAR and MD Studies

Pharmacophore-based virtual screening, molecular docking, and molecular dynamics investigation for the identification of novel, marine aromatase inhibitors

Computational Screening of Some Phytochemicals to Identify Best Modulators for Ligand Binding Domain of Estrogen Receptor Alpha

Anticancer Potential of Phytochemicals Against Breast Cancer: Molecular Docking and Simulation Approach

Exploring the Untapped Potential of Marine Sponge Compounds as Anticancer Agents against ERα of Breast Cancer

Molecular Docking , ADMET and Pharmacokinetic properties predictions of some di-aryl Pyridinamine derivatives as Estrogen Receptor (Er+) Kinase Inhibitors

Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme

Screening of phytochemicals from Clerodendrum inerme (L.) Gaertn as potential anti-breast cancer compounds targeting EGFR: an in-silico approach

In silico analysis of potential inhibitors for breast cancer targeting 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) catalyses

Exploring okra-derived compounds as prospective aromatase inhibitors: a computational study for enhanced breast cancer therapy

Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy

Structure-Based Multi-Targeted Molecular Docking and Dynamic Simulation of Soybean-Derived Isoflavone Genistin as a Potential Breast Cancer Signaling Proteins Inhibitor

Docking Study, ADMET Profiling of the Designed 3-Chlorobenzo[b]thiophene-2-Carbonyl Chloride Derivatives: Promising Anti-Breast Cancer Activity